Patent SG-11201803813U-A (SG)
Title: 1,3,4-thiadiazole compounds and their use in treating cancer
Inventor: FINLAY MAURICE
IPC: C07D417/14
Filed: 2016-11-30
Abstract: Title: 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER (I) (57) : A compound of Foiinula (I) or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl, 5- chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-y1; R can be hydrogen, fluoro, or methoxy; R 1 can be hydro- gen, methoxy, difluoromethoxy, or trifluoromethoxy; and R 2 can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1. (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 1111111111111111111111111111111111111111111 11111111111111R111111111111111 (10) International Publication Number WO 2017/093300 Al WIPO I PCT (43) International Publication Date 8 June 2017 (08.06.2017) (74) Agent: COOK, Andrew; AstraZeneca Intellectual Prop- erty Mereside, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) (51) International Patent Classification: C07D 417/14 (2006.01) A61K 31/53 (2006.01) A61K 31/501 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2016/079251 (22) International Filing Date: 30 November 2016 (30.11.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/260787 30 November 2015 (30.11.2015) US (71) Applicants: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). CANCER RESEARCH TECHNO- LOGY LIMITED [GB/GB]; Angel Building 407 St John Street, London EC1V 4AD (GB). (72) Inventors: FINLAY, Maurice, Raymond, Verschoyle; AstraZeneca R&D Cambridge, Darwin Building Cam- bridge Science Park, Milton Road, Cambridge Cambridge- shire CB4 OFZ (GB). NISSINK, Johannes, Wilhelmus, Maria; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Canbridgeshire CB4 OWG (GB). CHARLES, Mark, David; CRT Discovery Laborat- ories, Jonas Webb Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). WOOD, Matt; AstraZeneca UG22 Redesmere Silk Road Business Park, Charter way, Macclesfield Cheshire SK10 2NX (GB). W O 20 17 /093300 Al